Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017149332) MIRABEGRON COCRYSTAL
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/149332 International Application No.: PCT/HU2016/050044
Publication Date: 08.09.2017 International Filing Date: 22.09.2016
IPC:
C07D 277/40 (2006.01) ,A61K 31/426 (2006.01)
[IPC code unknown for C07D 277/40][IPC code unknown for A61K 31/426]
Applicants:
EGIS GYÓGYSZERGYÁR ZRT. [HU/HU]; Keresztúri út 30-38. 1106 Budapest, HU
Inventors:
VOLK, Balázs; HU
KOVÁCS, József; HU
KÁTAINÉ FADGYAS, Katalin; HU
VARGA, Zoltán; HU
MRAVIK, András; HU
VIRÁG, Attila; HU
NAGY, Tamás; HU
HALÁSZ, Judit; HU
TÓTHNÉ LAURITZ, Mária; HU
JANINÉ VAKULYA, Gabriella; HU
Agent:
KOVÁRI LLC; Attila út 125. 1012 Budapest, HU
Priority Data:
P160005101.02.2016HU
Title (EN) MIRABEGRON COCRYSTAL
(FR) CO-CRISTAL DE MIRABEGRON
Abstract:
(EN) The subject of the present invention is the cocrystal form of (R)-2-(2-aminothiazol-4-yl)-4'- {2-[(2-hydroxy-2-phenyl)ethylamino]ethyl}acetamide (mirabegron) of formula (1) and halide salt of an alkaline earth metal or halide salt of a d-yield metal and its solvates, where the alkaline earth metal is preferably calcium or magnesium and the d-yield metal is preferably zinc. The more specific subject of the present invention is the cocrystal form of mirabegron of formula (2) consisting of 2 molecules of mirabegron, 1 molecule of magnesium-chloride (MgC2) and 2 molecules of water (H2O), its preparation method, a pharmaceutical composition comprising the cocrystal of formula (2) and the therapeutical use of the latter pharmaceutical composition.
(FR) La présente invention concerne la forme co-cristalline de (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phényl)éthylamino]éthyl}acétamide (mirabegron) de formule (1) et un sel d'halogénure d'un métal alcalino-terreux ou d'un sel d'halogénure d'un métal du bloc d et de ses solvants, le métal alcalino-terreux étant de préférence du calcium ou du magnésium et le métal du bloc d étant de préférence du zinc. La présente invention concerne en particulier la forme co-cristalline de mirabegron de formule (2) comprenant 2 molécules de mirabegron, 1 molécule de chlorure de magnésium (MgC2) et 2 molécules d'eau (H2O), son procédé de préparation, une composition pharmaceutique comprenant le co-cristal de formule (2) et l'utilisation thérapeutique de ladite composition pharmaceutique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: ???LANGUAGE_SYMBOL_HU??? (HU)